Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

High remission rates for new CLL treatment

Prof John Seymour - Peter MacCallum Cancer Centre, Victoria, Australia

High remission rates for new CLL treatment ( Prof John Seymour - Peter MacCallum Cancer Centre, Victoria, Australia )

CLL from a patient and physician perspective

Dr Brian Koffman MD – Medical Director of the CLL Society

CLL from a patient and physician perspective ( Dr Brian Koffman MD – Medical Director of the CLL Society )

Risk of bleeding-related adverse events in ibrutinib treated CLL patients

Dr Adrian Weistner - National Heart, Lung and Blood Institute, Maryland, USA

Risk of bleeding-related adverse events in ibrutinib treated CLL patients ( Dr Adrian Weistner - National Heart, Lung and Blood Institute, Maryland, USA )

Crystallography of the B-cell receptor immunoglobulin in CLL patients

Prof Paolo Ghia - San Raffaele University, Milan, Italy

Crystallography of the B-cell receptor immunoglobulin in CLL patients ( Prof Paolo Ghia - San Raffaele University, Milan, Italy )

Harmonisation of CLL diagnosis and detection of residual disease monitoring by...

Dr Andrew Rawstron - St James Institute of Oncology, Leeds, UK

Harmonisation of CLL diagnosis and detection of residual disease monitoring by flow cytometry ( Dr Andrew Rawstron - St James Institute of Oncology, Leeds, UK )

Results of subgroup analysis of the HELIOS trial

Dr Paula Cramer – University of Cologne, Cologne, Germany

Results of subgroup analysis of the HELIOS trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )

Primary results from the MABLE phase IIIb study

Dr Anne-Sophie Michallet - Centre Hospitalier Lyon-Sud, Lyon, France

Primary results from the MABLE phase IIIb study ( Dr Anne-Sophie Michallet - Centre Hospitalier Lyon-Sud, Lyon, France )

Highlights from the iwCLL conference: B-cell receptor Btk, PI3K and multi...

Dr Amy Johnson – The Ohio State University, Columbus, USA

Highlights from the iwCLL conference: B-cell receptor Btk, PI3K and multi-molecular BCR inhibitors ( Dr Amy Johnson – The Ohio State University, Columbus, USA )

Will chemotherapy remain the cornerstone of CLL management?

Prof Clemens Wendtner - Klinikum Schwabing, Munich, Germany

Will chemotherapy remain the cornerstone of CLL management? ( Prof Clemens Wendtner - Klinikum Schwabing, Munich, Germany )

Phase II study of idelalisib monotherapy in older CLL patients

Dr Andrew Zelenetz – Memorial Sloan Kettering Cancer Center, New York, USA

Phase II study of idelalisib monotherapy in older CLL patients ( Dr Andrew Zelenetz – Memorial Sloan Kettering Cancer Center, New York, USA )

History of the B-cell in its 50th anniversary year

Prof Max Cooper - Emory University, Atlanta, USA

History of the B-cell in its 50th anniversary year ( Prof Max Cooper - Emory University, Atlanta, USA )

Translational research and the future of CLL treatment

Prof Steven Coutré – Stanford University School of Medicine, Stanford, USA

Translational research and the future of CLL treatment ( Prof Steven Coutré – Stanford University School of Medicine, Stanford, USA )

More from ecancer